U.S. stock index futures rose on Thursday as investors looked ahead to the start of a central banking summit in Jackson Hole, Wyoming.US Marketsread more
"My sense was we've added accommodation and it wasn't required in my view," George tells CNBC's Steve Liesman.Investingread more
Apple plans to unveil three new iPhones in September, including two new "Pro" models and a successor to the iPhone XR, Bloomberg reported Thursday.Technologyread more
Corporate profits posted modest growth in the second quarter as companies brace for slowing global growth.Retailread more
Kraft has filed a contempt motion against the CFTC over a press release announcing the $16 million fine to settle claims of manipulating wheat prices.Food & Beverageread more
Former Prudent Bear Fund manager David Tice is urging investors to brace for a massive downturn.Trading Nationread more
A ruling against J&J could mean more big payouts in similar cases across the country.Health and Scienceread more
Democratic candidates face an August 28 deadline to qualify for the September debate.2020 Electionsread more
Sterling hit a three-week high against the dollar Thursday after German Chancellor Angela Merkel said a solution to the Irish "backstop" is possible before the October 31...Europe Economyread more
Target shares closed Wednesday up more than 20%, after the retailer reported impressive profit growth and a spike in traffic that surpassed analysts' expectations.Retailread more
"If I could borrow without paying any interest, or ever pay the money back, I would borrow as much as I could, too," the 'Trumponomics' co-author says.Economyread more
A biotech firm hopes that DNA will hold the answer to fighting that mother of diseases: aging.
Human Longevity, Inc., says it can sequence a person's DNA and combine it with other clinical tests to identify how long someone will live, and what can be done to extend a patient's life, even before a budding disease, such as cancer, shows symptoms.
The La Jolla, California-based company is compiling a massive database of DNA and clinical information to find ways to extend the human lifespan, and runs a clinic where $25,000 will get a full day of tests and a complete profile totaling about one petabyte of medical information.
"It is the most comprehensive physical you can get, " said company co-founder J. Craig Venter, on "Squawk Box." The company looks to find actionable solutions for any medical issues that arise.
Venter said seemingly healthy patients getting the tests have discovered cancer in its earliest stages — when the disease is usually most treatable. The tests are also capable of identifying the risks of getting certain diseases later in life.
"We are learning that we are a DNA software driven species," Venter said, "and that your software determines everything about your life, including how long you are going to live."
But DNA can also give clues about how diseases might be treated. The disease-producing genetic quirks its systems identify can be used as "pharmaceutical targets, so that people with those genetic changes don't die," Venter said.
The information is analyzed by artificial intelligence "in a way that no human doctor could do, " said company co-founder Peter Diamandis in the segment.
At $25,000, it is not exactly cheap. "But we have a version of it we think we can do for a few thousand dollars, because the two most important aspects of the treatment are the sequencing and the MRI imaging," he said.
Indeed, genomic sequencing may soon cost next to nothing, Venter said.
Venter led one of the two teams of scientists who first sequenced the human genome. Back then it cost about $100 million to sequence an entire human genome, today Venter can do it for less than $1,500.